Allegations of excessive pricing of Trastuzumab, impacting thousands of SA women living with the condition
The Cancer Alliance, represented by SECTION27, has been admitted as an intervening party in the Competition Commission’s excessive pricing case against Roche Holdings, a Switzerland-based multinational healthcare company, and its subsidiaries, over breast cancer drug pricing.
The case, brought before the Competition Tribunal, alleges that Roche charged excessively high prices for Trastuzumab, a life-saving treatment for HER2-positive breast cancer.
Trastuzumab is used to stop the development of these tumour cells to prevent the cancer from spreading and death. In South Africa, Trastuzumab is sold under Roche’s brand name Herceptin in the private healthcare sector and under the brand name Herclon in the public healthcare sector.
The Competition Commission argues that these prices restricted access to…